ALGN

Align is a high-quality franchise being asked to grow into a price it no longer earns. Gross margin is a healthy 67.2% and the balance sheet is a fortress — $1.09B cash, liabilities/equity of just 0.54x, and $466M of buybacks (up 32%) that shrank the share count 3.1%. But underneath the quality, the business has stalled: revenue has been pinned near $4B for four straight years ($3.95B in 2021 → $4.03B in 2025, just +0.9% YoY), and net income has roughly halved from the $772M FY2021 peak to $410M, declining again this year. The earnings story is worse than the top line — FY2025 operating income fell 10.2% and operating cash flow dropped 19.6% to $593M, so the flat EPS ($5.65, +0.5%) is being manufactured by buybacks, not by the business.

The 10-K explains why this is structural, not a one-quarter wobble. Management states orthodontic starts have been down for four consecutive years and that doctors are shifting patients to wires and brackets 'in lieu of clear aligners' — a competitive substitution that got 'more pronounced' in Q2 2025 and that they expect to 'continue' while consumer uncertainty impairs discretionary spending. They cite tariff volatility, inflation, and higher rates dampening dental patient demand, plus iTero's Israel headquarters as a live geopolitical exposure. The company began a multi-quarter restructuring in Q3–Q4 2025 to 'streamline operations' — confirmation that costs, not demand, are now the lever. The 63.7% jump in D&A also flatters cash flow relative to reported operating income.